Current Month 2007
Article Features
  Aging Population is Causing Major Increase in the Cancer Burden
Hormone Drug Type Makes Survival Difference in Advanced Breast Cancer
Growth Factors Given with Chemotherapy Associated with Increased Risk of Blood Diseases
Study Finds Flaws in Second Phase of Cancer Clinical Trials
Estrogen Interferes with Immune Surveillance in Breast Cancer
Novel Computed Imaging Technique Uses Blurry Images to Enhance View
Inadequate Communication Reduces Benefits of Mammogram Screening for Black Women
Men with Breast Cancer Face High Risk of Second Cancer
Obesity Drug Helps Unlock Clues About Cancer
Radiation Therapy Reduces Cancer Recurrence in Older Breast Cancer Patients
Poorer Women More Likely to Get Reduced Chemotherapy Dose
Spirituality Plays Important Role in Breast Cancer Information Processing for African-American Women
Peptide Vaccine Fights Off Breast Tumors with Aid of Bacteria-Mimicking Agents

Adding Radiation Decreases Breast Cancer Recurrence

Radiotherapy after breast conserving surgery for breast cancer reduces recurrence and prevents development of additional breast tumors in older women with early stage breast disease, according to a new study.

Published in the journal Cancer, the study suggests that women also benefit from the recommended five years of tamoxifen treatment for hormone responsive tumors. Among women over 65 and treated with breast conserving surgery, the risk of local or regional recurrence increased up to 3.5 times if they did not receive radiation after their surgery.

Great strides have been made in breast cancer treatment. Breast conserving surgery in combination with radiotherapy and mastectomy provide women with two good options for their initial treatment. Augmenting surgery with hormone modulating drugs, such as tamoxifen, further improves survival and reduces recurrence.

Women over 65 are at the highest risk for breast cancer and make up half of those diagnosed. However, they are less likely to receive standard therapy, particularly radiotherapy after breast conserving surgery, than younger women. Making treatment recommendations for older patients, who may have more comorbidities than younger patients, is complicated by under-representation of older women in clinical trials and prognostic studies.

Read More of the Main Article

Visit the Ezine

Visit the BreastCenter

Visit the Quality Corner
Avon Breast Cancer Crusade - AVON the company for women

  This website is supported in part by an unrestricted educational grant provided by Avon